IP
AXDX

Isthmus Partners’s Accelerate Diagnostics AXDX Stock Holding History

Isthmus Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-60
Closed -$14K – 145
2018
Q3 		$14K Hold
60
– – ﹤0.01% 239
2018
Q2 		$13K Hold
60
– – ﹤0.01% 229
2018
Q1 		$14K Buy
60
+20
+50% +$5.25K ﹤0.01% 220
2017
Q4 		$10K Buy
+40
New +$9.38K ﹤0.01% 236

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CAM
Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Isthmus Partners's AXDX Position: Q4 2018 in Review

Isthmus Partners sold out of Accelerate Diagnostics (AXDX) in Q4 2018, closing a stake of 60 shares — an estimated $14K sold.

Isthmus Partners first reported a position in AXDX in Q4 2017 and held it in 4 quarters. The position peaked at $14K in Q3 2018. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2018.

  • Isthmus Partners reported no remaining Accelerate Diagnostics position as of Q4 2018 after selling out during the quarter.
  • Isthmus Partners sold 60 Accelerate Diagnostics shares in Q4 2018, an estimated $14K.
  • Isthmus Partners first reported a position in Accelerate Diagnostics in Q4 2017 and held it in 4 quarters.
  • Isthmus Partners's Accelerate Diagnostics position peaked at $14K in Q3 2018.
  • 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2018.

Based on Isthmus Partners's 13F filing for Q4 2018, filed 4 Feb 2019.